LAUSR

“Endovascular versus surgical treatment of cranial dural arteriovenous fistulas: A single center 8-years’ experience” was published in the January 2022 Issue of Acta Neurochirurgica [12]. Based on our findings from 112 dural arteriovenous fistulas (dAVFs) in 107 patients, we recommended endovascular therapy (EVT) as the first-line treatment modality in Djindjian types I and II, and in non-hemorrhagic type III/IV dAVFs, but microsurgery as the first-line treatment in acute hemorrhagic dAVFs. Our recommendation of microsurgery in acute hemorrhagic dAVFs was based on three observations: (1) frequent early dAVF rebleed (35%, with a median time of 7.5 h from ictus to rebleed), (2) significantly shorter treatment delay from hospital arrival to treatment with microsurgery as compared to EVT (13 vs 33 h), and (3) a significantly higher frequency of complete dAVF occlusion with microsurgery as compared to EVT (100% vs 50%).